The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Central Administration of Glucagon-Like Peptide-1 Activates Hypothalamic Neuroendocrine Neurons in the Rat
Abstract
Within the central nervous system, glucagon-like peptide-1-(7-36) amide (GLP-1) acts as a transmitter, inhibiting feeding and drinking behavior. Hypothalamic neuroendocrine neurons are centrally involved in the regulatory mechanisms controlling these behaviors, and high densities of GLP-1 binding sites are present in the rat hypothalamus. In the present study we have, over a period of 4 h, followed the effect of centrally injected GLP-1 on plasma levels of the neurohypophysial hormones vasopressin and oxytocin. Plasma levels of corticosterone and glucose were also followed across time after central administration of GLP-1. In conscious, freely moving, and unstressed rats, central injection of GLP-1 significantly elevated plasma levels of vasopressin 15 and 30 min after administration (basal, 0.8 +/- 0.2 pg/ml; 15 min, 7.5 +/- 2.0 pg/ml; 30 min, 5.6 +/- 1.1 pg/ml; mean +/- SEM) and elevated corticosterone 15 min after administration (52 +/- 13 vs. 447 +/- 108 ng/ml, basal vs. 15 min; mean +/- SEM). In contrast, plasma oxytocin levels were unaffected by intracerebroventricular (icv) injections of GLP-1 over a period of 4 h after the injection. The animals given a central injection of GLP-1 developed transient hypoglycemia 20 min after the injection, which was fully restored to normal levels at 30 min. Furthermore, we used c-fos immunocytochemistry as an index of stimulated neuronal activity. The distribution and quantity of GLP-1-induced c-fos immunoreactivity were evaluated in a number of hypothalamic neuroendocrine areas, including the magnocellular neurons of the paraventricular (PVN) and supraoptic (SON) nuclei and the parvicellular neurons of the medial parvicellular subregion of the PVN. The number of c-fos-expressing nuclei in those areas was assessed 30, 60, and 90 min after icv administration of GLP-1. Intracerebroventricular injection of GLP-1 induced c-fos expression in the medial parvicellular subregion of the PVN as well as in magnocellular neurons of the PVN and SON. A slight induction of c-fos expression was seen in the arcuate nucleus and the nucleus of the solitary tract, including the area postrema. In contrast, the subfornical organ, which is a rostrally situated circumventricular organ, was free of c-fos-positive cells after central administration of GLP-1. When the GLP-1 antagonist exendin-(9-39) was given before the GLP-1, c-fos expression in these neuroendocrine areas was almost completely abolished, suggesting that the effect of GLP-1 on c-fos expression is mediated via specific receptors. A dual labeling immunocytochemical technique was used to identify the phenotypes of some of the neurons containing c-fos-immunoreactive nuclei. Approximately 80% of the CRH-positive neurons in the hypophysiotropic medial parvicellular part of the PVN coexpressed c-fos 90 min after icv GLP-1 administration. In contrast, very few (approximately 10%) of the vasopressinergic magnocellular neurons of the PVN/SON contained c-fos-positive nuclei, whereas approximately 38% of the magnocellular oxytocinergic neurons expressed c-fos-positive nuclei in response to GLP-1 administration. This study demonstrates that central administration of the anorectic neuropeptide GLP-1 activates the central CRH-containing neurons of the hypothalamo-pituitary-adrenocortical axis as well as oxytocinergic neurons of the hypothalamo-neurohypophysial tract. Therefore, we conclude that GLP-1 activates the hypothalamo-pituitary-adrenocortical axis primarily through stimulation of CRH neurons, and this activation may also be responsible for the inhibition of feeding behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Expression of c- fos Protein in Brain: Metabolic Mapping at the Cellular Level
Sagar, S. M., Sharp, F. R., & Curran, T. (1988) · Science · doi:10.1126/science.3131879 · Cited by 1,925
Cholecystokinin decreases food intake in rats.
Gibbs, J., Young, R. C., & Smith, G. P. (1973) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0034870 · Cited by 1,491
NEUROPEPTIDE Y AND HUMAN PANCREATIC POLYPEPTIDE STIMULATE FEEDING BEHAVIOR IN RATS
Clark, J. T., Kalra, P. S., Crowley, W. R., & Kalra, S. P. (1984) · Endocrinology · doi:10.1210/endo-115-1-427 · Cited by 1,276
A receptor subtype involved in neuropeptide-Y-induced food intake
Gerald, C., Walker, M. W., Criscione, L., Gustafson, E. L., Batzl-Hartmann, C., Smith, K. E., Vaysse, P., Durkin, M. M., Laz, T. M., Linemeyer, D. L., et al. (1996) · Nature · doi:10.1038/382168a0 · Cited by 891
Functions of Angiotensin in the Central Nervous System
Phillips, I. M. (1987) · Annual Review of Physiology · doi:10.1146/annurev.ph.49.030187.002213 · Cited by 742
Stanley, B. G., & Leibowitz, S. F. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.11.3940 · Cited by 741
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Research works printed but not linked: 8
- Schick, 1993, Glucagon-like peptide-1: a novel brain peptide involved in feeding regulation In: Ditschuneit H, Gries FA, Hauner H, Schusdziarra V, Wechsler JG (eds) Obesity in Europe, Libbey, London, pp, 363
- Tang-Christensen, 1994, GLP-1 and its receptors in the central nervous system are powerful regulators of autonomic functions in the brain., Soc Neurosci Abstr, 24, 561
- Tang-Christensen, 1996, Brain GLP-1 (7–36) amide receptors play a major role in regulation of food and water intake, Am J Physiol, 271, R848
- Swanson, 1987, The hypothalamus, In: Björklund A, Hökfelt T, Swanson LW (eds) Handbook of Chemical Neuroanatomy. Elsevier, Amsterdam, pp, 1
- Thiele, 1996, Central infusion of leptin (OB protein) and GLP-1(7–36)amide differentially stimulate c-fos expression in rat brain., Soc Neurosci Abstr, 22, 556
- Panksepp, 1996, Potent suppressive effects of the putative satiety agent GLP-1 on social-emotional behaviors., Soc Neurosci Abstr, 22, 15
- Falke, 1991, Modulation of oxytocin and vasopressin release at the level of the neurohypophysis., Prog Neurobiol, 36, 465, 10.1016/0301-0082(91)90013-Q · doi:10.1016/0301-0082(91)90013-q
- Renaud, 1987, Cholecystokinin and gastric distension activate oxytocinergic cells in the rat hypothalamus, Am J Physiol, 253, R661
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Self-citationKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“In rodents, central injection of GLP-1 increases levels of adrenocorticotropin and corticosterone (Larsen et al., 1997; Kinzig et al., 2003), and GLP-1 antagonists block increases in these hormones induced by the LiCl (Kinzig et al., 2003).”
BackgroundSemaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Yamamoto, H., Lee, C. E., Marcus, J., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L. L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15595 · Cited by 473
Central Control of Body Weight and Appetite
Woods, S. C., & D'Alessio, D. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1630 · Cited by 458
Gastrointestinal hormones and food intake
Strader, A. D., & Woods, S. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.10.043 · Cited by 447
Yamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Minireview: The Glucagon-Like Peptides
Drucker, D. J. (2001) · Endocrinology · doi:10.1210/en.142.2.521 · Cited by 421
Gonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity
Silva, A. D., & Bloom, S. R. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.1.10 · Cited by 373
“Furthermore, there are projections to the dorsomedial hypothalamus.(64) It is well established that administration of GLP-17-36 amide peripherally or centrally leads to reduced food intake in rodents, whereas co-administration of an antagonist of GLP-1 (exendin9-39) abolishes this effect.”
BackgroundEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Gastrointestinal hormones regulating appetite
Chaudhri, O., Small, C., & Bloom, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2006.1856 · Cited by 346
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
Meeran, K., O’Shea, D., Edwards, C. M. B., Turton, M. D., Heath, M. M., Gunn, I., Abusnana, S., Rossi, M., Small, C. J., Goldstone, A. P., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6421 · Cited by 303
Saito, E.-S., Kaiya, H., Tachibana, T., Tomonaga, S., Denbow, D. M., Kangawa, K., & Furuse, M. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.09.003 · Cited by 303
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Tang-Christensen, M., Larsen, P. J., Thulesen, J., Rømer, J., & Vrang, N. (2000) · Nature Medicine · doi:10.1038/77535 · Cited by 269
Self-citationThe effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
Meek, C. L., Lewis, H. B., Reimann, F., Gribble, F. M., & Park, A. J. (2016) · Peptides · doi:10.1016/j.peptides.2015.08.013 · Cited by 269
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
GLP-1 and energy balance: an integrated model of short-term and long-term control
Barrera, J. G., Sandoval, D. A., D'Alessio, D. A., & Seeley, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.77 · Cited by 220
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Nogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., López, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5977-08.2009 · Cited by 182
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
Burmeister, M. A., Ayala, J. E., Smouse, H., Landivar-Rocha, A., Brown, J. D., Drucker, D. J., Stoffers, D. A., Sandoval, D. A., Seeley, R. J., & Ayala, J. E. (2017) · Diabetes · doi:10.2337/db16-1102 · Cited by 136
MacLusky, N. J., Cook, S., Scrocchi, L., Shin, J., Kim, J., Vaccarino, F., Asa, S. L., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.2.7326 · Cited by 133
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Tonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3938-z · Cited by 126
Role of oxytocin signaling in the regulation of body weight
Blevins, J. E., & Ho, J. M. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9260-x · Cited by 108
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Brain activation following peripheral administration of the GLP-1 receptor agonist exendin-4
Baraboi, E.-D., St-Pierre, D. H., Shooner, J., Timofeeva, E., & Richard, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00424.2010 · Cited by 79
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
Guerrero-Hreins, E., Goldstone, A. P., Brown, R. M., & Sumithran, P. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110303 · Cited by 62
α‐Melanocyte‐Stimulating Hormone and Oxytocin: A Peptide Signalling Cascade in the Hypothalamus
Sabatier, N. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01464.x · Cited by 54
Chen, X.-Y., Chen, L., Yang, W., & Xie, A.-M. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.793004 · Cited by 52
Glucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
A Possible Role of GLP-1 in the Pathophysiology of Early Dumping Syndrome
Yamamoto, H., Mori, T., Tsuchihashi, H., Akabori, H., Naito, H., & Tani, T. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-3046-2 · Cited by 43
Effects of nutrition on neuro-endocrine stress responses
Rohleder, N., & Kirschbaum, C. (2007) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e3281e38808 · Cited by 40
Body weight regulation via MT1-MMP-mediated cleavage of GFRAL
Chow, C. F. W., Guo, X., Asthana, P., Zhang, S., Wong, S. K. K., Fallah, S., Che, S., Gurung, S., Wang, Z., Lee, K. B., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00529-5 · Cited by 37
Acute and repeated restraint differentially activate orexigenic pathways in the rat hypothalamus
Chagra, S. L., Zavala, J. K., Hall, M. V., & Gosselink, K. L. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2010.11.006 · Cited by 35
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Fortin, S. M., Chen, J. C., Petticord, M. C., Ragozzino, F. J., Peters, J. H., & Hayes, M. R. (2023) · Science Advances · doi:10.1126/sciadv.adh0980 · Cited by 32
Maejima, Y., Yokota, S., Shimizu, M., Horita, S., Kobayashi, D., Hazama, A., & Shimomura, K. (2021) · Nutrition & Metabolism · doi:10.1186/s12986-021-00582-z · Cited by 21
Iranmanesh, A., Lawson, D., Dunn, B., & Veldhuis, J. D. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0682 · Cited by 17
Central Control of Glucose Homeostasis
Puglianiello, A., & Cianfarani, S. (2006) · The Review of Diabetic Studies · doi:10.1900/rds.2006.3.54 · Cited by 14
“Some preliminary studies demonstrated that ICV administration of GLP-1 activates primarily the central CRH-containing neurons of the hypothalamopituitary-adrenocortical axis and this activation may be responsible for the reduction of plasma glucose levels [53].”
BackgroundVolcko, K. L., Brakey, D. J., McNamara, T. E., Meyer, M. J., McKay, N. J., Santollo, J., & Daniels, D. (2022) · Appetite · doi:10.1016/j.appet.2022.105943 · Cited by 12
Metadata
- Authors
- Larsen, P. J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1997-10-01
- Volume
- 138
- Issue
- 10
- Pages
- 4445-4455
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2006841717
- Cited by
- 316
- References
- 63
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.